215 related articles for article (PubMed ID: 8500222)
1. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C.
Akinaga S; Nomura K; Gomi K; Okabe M
Cancer Chemother Pharmacol; 1993; 32(3):183-9. PubMed ID: 8500222
[TBL] [Abstract][Full Text] [Related]
2. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells.
Akinaga S; Nomura K; Gomi K; Okabe M
Cancer Chemother Pharmacol; 1994; 33(4):273-80. PubMed ID: 7506638
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models.
Akinaga S; Gomi K; Morimoto M; Tamaoki T; Okabe M
Cancer Res; 1991 Sep; 51(18):4888-92. PubMed ID: 1893379
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effect of KT6124, a novel derivative of protein kinase inhibitor K-252a, and its mechanism of action.
Akinaga S; Ashizawa T; Gomi K; Ohno H; Morimoto M; Murakata C; Okabe M
Cancer Chemother Pharmacol; 1992; 29(4):266-72. PubMed ID: 1537071
[TBL] [Abstract][Full Text] [Related]
5. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation.
Sugiyama K; Shimizu M; Akiyama T; Tamaoki T; Yamaguchi K; Takahashi R; Eastman A; Akinaga S
Int J Cancer; 2000 Mar; 85(5):703-9. PubMed ID: 10699952
[TBL] [Abstract][Full Text] [Related]
6. UCN-01 (7-hydoxystaurosporine) inhibits in vivo growth of human cancer cells through selective perturbation of G1 phase checkpoint machinery.
Abe S; Kubota T; Otani Y; Furukawa T; Watanabe M; Kumai K; Akiyama T; Akinaga S; Kitajima M
Jpn J Cancer Res; 2001 May; 92(5):537-45. PubMed ID: 11376563
[TBL] [Abstract][Full Text] [Related]
7. UCN-01 (7-hydroxystaurosporine) inhibits the growth of human breast cancer xenografts through disruption of signal transduction.
Koh J; Kubota T; Migita T; Abe S; Hashimoto M; Hosoda Y; Kitajima M
Breast Cancer; 2002; 9(1):50-4. PubMed ID: 12196722
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Patel V; Lahusen T; Leethanakul C; Igishi T; Kremer M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS; Senderowicz AM
Clin Cancer Res; 2002 Nov; 8(11):3549-60. PubMed ID: 12429646
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C.
Morimoto M; Ashizawa T; Ohno H; Azuma M; Kobayashi E; Okabe M; Gomi K; Kono M; Saitoh Y; Kanda Y
Cancer Res; 1991 Jan; 51(1):110-5. PubMed ID: 1988076
[TBL] [Abstract][Full Text] [Related]
10. The effect of UCN-01 (7-hydroxystaurosporine), a potent inhibitor of protein kinase C, on fractionated radiotherapy or daily chemotherapy of a murine fibrosarcoma.
Tsuchida E; Urano M
Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1153-61. PubMed ID: 9392558
[TBL] [Abstract][Full Text] [Related]
11. UCN-01 dose-dependent inhibition of normal hyperproliferative cells in mice.
Redkar AA; Meadows GG; Daoud SS
Int J Oncol; 2001 Jul; 19(1):193-9. PubMed ID: 11408942
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole.
Akiyama T; Shimizu M; Okabe M; Tamaoki T; Akinaga S
Anticancer Drugs; 1999 Jan; 10(1):67-78. PubMed ID: 10194549
[TBL] [Abstract][Full Text] [Related]
13. Combined antitumor activity of 7-hydroxystaurosporine (UCN-01) and tamoxifen against human breast carcinoma in vitro and in vivo.
Koh J; Kubota T; Koyama T; Migita T; Hashimoto M; Hosoda Y; Kitajima M
Breast Cancer; 2003; 10(3):260-7. PubMed ID: 12955040
[TBL] [Abstract][Full Text] [Related]
14. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells.
Akiyama T; Yoshida T; Tsujita T; Shimizu M; Mizukami T; Okabe M; Akinaga S
Cancer Res; 1997 Apr; 57(8):1495-501. PubMed ID: 9108451
[TBL] [Abstract][Full Text] [Related]
15. Differing effects of staurosporine and UCN-01 on RB protein phosphorylation and expression of lung cancer cell lines.
Shimizu E; Zhao MR; Nakanishi H; Yamamoto A; Yoshida S; Takada M; Ogura T; Sone S
Oncology; 1996; 53(6):494-504. PubMed ID: 8960146
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo.
Tsuruo T; Sudo Y; Asami N; Inaba M; Morimoto M
Cancer Chemother Pharmacol; 1990; 27(2):89-93. PubMed ID: 2123421
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2.
Wang Q; Worland PJ; Clark JL; Carlson BA; Sausville EA
Cell Growth Differ; 1995 Aug; 6(8):927-36. PubMed ID: 8547221
[TBL] [Abstract][Full Text] [Related]
18. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.
Wang Q; Fan S; Eastman A; Worland PJ; Sausville EA; O'Connor PM
J Natl Cancer Inst; 1996 Jul; 88(14):956-65. PubMed ID: 8667426
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.
Schwartz GK; Farsi K; Maslak P; Kelsen DP; Spriggs D
Clin Cancer Res; 1997 Sep; 3(9):1467-72. PubMed ID: 9815832
[TBL] [Abstract][Full Text] [Related]
20. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma.
Mack PC; Gandara DR; Lau AH; Lara PN; Edelman MJ; Gumerlock PH
Cancer Chemother Pharmacol; 2003 Apr; 51(4):337-48. PubMed ID: 12721762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
